Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

Journal of Dermatology

Volumn 39, Issue 3, 2012, Pages 253-259

  Torii, Hideshi ^a   Sato, Noriko ^b   Yoshinari, Toru ^b   Nakagawa, Hidemi ^c  

^a Social Insurance Central General Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Mitsubishi Tanabe Pharma   (Japan)

Author keywords

Dermatology Life Quality Index of 0 or 1; infliximab; psoriasis; Psoriasis Area and Severity Index 90; treatment goal

Indexed keywords

INFLIXIMAB;

ADULT; AGE; ARTICLE; CLINICAL ASSESSMENT TOOL; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX 90; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PSORIATIC ERYTHRODERMA; PUSTULAR PSORIASIS; QUALITY OF LIFE; RATING SCALE;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 84857642458     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01459.x     Document Type: Article

References (20)

1. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407. (Pubitemid 29418506)
2. Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006; 154: 844-849.
3. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis. Arch Dermatol 2010; 146: 891-895.
4. Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl.2): 5-70.
5. Katugampola RP, Lewis VJ, Finlay AY,. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol 2007; 156: 945-950. (Pubitemid 46642856)
6. Reich K, Ortonne J-P, Kerkmann U, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 2010; 221: 172-178.
7. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-542. (Pubitemid 39278071)
8. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
9. Torii H, Nakagawa H, the Japanese infliximab study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
10. Torii H, Nakagawa H, the Japanese infliximab study investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38: 321-334.
11. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563. (Pubitemid 28459913)
12. Wozel G, Klein E, Mrowietz U, Reich K, Sebastian M, Streit V,. Scalp psoriasis. J Dtsch Dermatol Ges 2011; 9: 70-74.
13. Reich K,. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009; 23 (Suppl.1): 15-21.
14. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K,. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372. (Pubitemid 351630108)
15. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684. (Pubitemid 351671884)
16. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459. (Pubitemid 34620190)
17. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1233-1238. (Pubitemid 47309743)
18. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T,. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009; 19: 478-487.
19. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol and Hepatol 2006; 4: 1248-1254. (Pubitemid 44512213)
20. Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with the clinical efficacy in Crohn's disease. Inflamm Bowel Dis 2011; doi: 10.1002/ibd.21886 (in press).